Glucotrack, Inc.

Nasdaq:GCTK

Surgical & Medical Instruments & Apparatus·RUTHERFORD, NJ

CEO

Goode Paul

Summary Financials

Revenue

$208,000

+378.3% YoY

FY 2020

Adj. EBITDA

-$7.1M

-3400.0% margin

FY 2024

Net Income

-$7.1M

-3412.0% margin

FY 2024

EPS (Diluted)

$34.18

FY 2024

Stock Price

$1.51

+4.1%

2026-03-06

52W Range

$1.31 – $30.51

P/E Ratio

0.0x

Market Cap

$1.4M

Cash

$4.5M

FY 2024

Total Debt

—

Net Cash

$4.5M

FY 2020

Enterprise Value

-$3.1M

Debt / EBITDA

0.6x

FY 2020

EV / EBITDA

0.4x

Employees

—

Revenue

$208,000

+378.3% YoY

FY 2020

Adj. EBITDA

-$7.1M

-3400.0% margin

FY 2024

Net Income

-$7.1M

-3412.0% margin

FY 2024

EPS (Diluted)

$34.18

FY 2024

Stock Price

$1.51

+4.1%

2026-03-06

52W Range

$1.31 – $30.51

P/E Ratio

0.0x

Market Cap

$1.4M

Cash

$4.5M

FY 2024

Total Debt

—

Net Cash

$4.5M

FY 2020

Enterprise Value

-$3.1M

Debt / EBITDA

0.6x

FY 2020

EV / EBITDA

0.4x

Employees

—